ANP (Atrial Natriuretic Peptide) vs NA-Selank Amidate
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →NA-Selank Amidate
NA-Selank Amidate (N-Acetyl Selank Amidate) is an enhanced version of Selank with improved stability and blood-brain barrier penetration. The modifications increase bioavailability and duration of cognitive and anxiolytic effects.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | NA-Selank Amidate |
|---|---|---|
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | Same core mechanism as Selank - modulates BDNF, serotonin, and norepinephrine systems. The N-acetyl group improves membrane permeability while the amidate modification increases enzymatic stability. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Intranasal: 100-400mcg 1-3 times daily. Lower doses needed compared to standard Selank due to enhanced bioavailability. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Primarily intranasal administration. Can be used sublingually. More stable in solution than standard Selank. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Generally well-tolerated. Possible mild fatigue or nasal irritation. Less frequent dosing needed than standard Selank. |
| Best For |